SPOTLIGHT: Genentech touts vision drug

Macular degeneration patients treated with Lucentis saw their sight sharpen so radically that they could meet vision requirements for driving, researchers said. In the trial, about 40 percent of the 716 patients achieved vision of 20/40 or better after 12 months. Genentech has put the drug on the fast track for FDA approval. Story

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.